Unleashing the Potential of Gene Therapies: Overcoming HTA Challenges

By Staff Writer

October 16, 2023

The Promise and Challenges of Gene Therapies

Gene therapies offer transformational benefits to patients, health systems, and society. However, several challenges hinder timely patient access. A report commissioned by Pfizer, penned by Besley et al. (2022), discusses the difficulties of health technology assessment (HTA) of gene therapies and proposes potential solutions.

 



Gene therapies, as defined by the European Medicines Agency (EMA), are medicines containing genes that lead to therapeutic, prophylactic, or diagnostic effects. They work by inserting ‘recombinant’ genes into the body to treat a variety of diseases, including genetic disorders, cancer, or long-term diseases.

Recommendations for Overcoming HTA Challenges

Based on a review of the literature and insights from an international panel of HTA and health economics experts, the authors propose six overarching recommendations. These recommendations aim to address the challenges in fully capturing the potential value of gene therapies as part of the HTA process and to improve the quality and acceptability of the evidence generated.

 


The recommendations are not specific to gene therapies and should be consistently applied across HTA of other treatments. However, due to the unique challenges presented by the HTA of gene therapies, if implemented, these recommendations are likely to have a larger impact on the assessment of gene therapies.

The report also assesses the extent to which these recommendations are being achieved in selected European countries, Australia, and Canada. It reviews the HTA outcomes of key gene therapies conducted in these countries to provide further understanding of the current state of play.

 

Reference url

Recent Posts

Innovative Strategies of MoonLake Immunotherapeutics HS in Targeting Inflammatory Diseases

By João L. Carapinha

August 30, 2025

MoonLake Immunotherapeutics HS, under the leadership of CEO Jorge Santos da Silva, is reimagining traditional biotech strategies with a concentrated approach to immunotherapeutic drug development. Utilizing innovative nanobody technology, the company is making strides in treating inflammatory dis...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...
The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...